Actelion Pharmaceuticals Ltd

Type: Company
Name: Actelion Pharmaceuticals Ltd (Actelion Ltd)
Nationality: Switzerland
Web Address: http://www.actelion.com/
Fact Sheet: Fact Sheet for Actelion Ltd
First reported Apr 17 2014 - Updated Apr 18 2014 - 2 reports

Actelion expands its PAH franchise in first quarter

Actelion Ltd of Switzerland continued to expand its franchise for treating pulmonary arterial hypertension (PAH) in the first quarter with the introduction of a new PAH product in North America and parts of Europe.LocationSwitzerland ... [Published MedNous - Apr 18 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Swiss Stocks Turn Higher, Led By UBS

Swiss stocks rallied to end the abbreviated week on high note, as traders went bargain hunting ahead of the Easter holiday.The Swiss Market Index (SMI) rose 52 points, or 0.63 percent, to 8,375.08.Big banks performed well, led by UBS with a 2 percent ... [Published RTTNews.com - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

European Stocks Rally For Modest Weekly Gain

European stocks fought back from early losses on Thursday as traders snapped up shares ahead of the Easter break.The Euro Stoxx 50 index of eurozone bluechip stocks rose 0.53 percent, for a modest weekly gain of 0.09.The German DAX rose 1 percent. The ... [Published RTTNews.com - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 9 reports

Actelion's CEO Discusses Q1 2014 Results - Earnings Call Transcript

Actelion Ltd ( OTCPK:ALIOF ) Q1 2014 Earnings Conference Call April 17, 2014 8:00 AM ETOperatorWelcome to the Actelion First Quarter 2014 Financial Results Conference Call. As a reminder all participant are in a listen-only mode. After the presentation, ... [Published Seeking Alpha - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Actelion Beats First-Quarter Earnings Expectations

ZURICH—Actelion Ltd. said rising sales of its key drugs helped it beat first-quarter earnings expectations and the company indicated it may raise full-year earnings guidance. Allschwill, Switzerland-based Actelion said first-quarter net income rose 31% ... [Published DailyMe.Com - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

What Falling Estimates & Price Mean for Discovery Laboratories (DSCO)

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security ... [Published Yahoo! Finance - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

Europe Stock-Index Futures Little Changed on Fed Remarks

European stock-index futures werelittle changed, with equities heading for a weekly gain, asFederal Reserve Chair Janet Yellen reiterated the central bankwill continue to support the economy. U.S. index futures werelittle changed, while Asian shares ... [Published Bloomberg - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

European Bourses Not Enjoying Bullish Winds From US Stocks

European stocks were little changed, with the Stoxx Europe 600 Index heading for a weekly gain, as Federal Reserve Chair Janet Yellen reiterated the central bank will continue to support the economy. U.S. index futures were also little changed, while ... [Published OANDA Forex Blog - Apr 17 2014]
Entities: Stocks, Oanda Corp, Index
First reported Apr 17 2014 - Updated Apr 17 2014 - 2 reports

BRIEF-Actelion rises 2 pct after Q1 results beat

8:02am BSTZURICH, April 17 (Reuters) - Actelion Ltd : * Shares rise 2 percent after Q1 results beat ... [Published Reuters UK - Apr 17 2014]
First reported Apr 17 2014 - Updated Apr 17 2014 - 1 reports

BB Biotech: Solid fundamental progress in the first quarter 2014

BB BIOTECH AG / . Processed and transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.Interim Report of BB Biotech AG as of March 31, 2014BB Biotech's portfolio reflects strong drug launches ... [Published Nasdaq - Apr 17 2014]
First reported Apr 13 2014 - Updated Apr 14 2014 - 2 reports

New Direction For Drugmakers Such As Merck & Co., Inc., Sanofi (France): Seeking Cure For Deadly Bowel Infection

Drugmakers led by Merck & Co. and Sanofi are searching for new weapons against a deadly bacteria behind hospital and nursing-home infections. Merck, Sanofi, Actelion Ltd. (ATLN) and Shire Plc (SHP) are among the companies vying to develop products to ... [Published BioSpace - Apr 14 2014]
First reported Apr 14 2014 - Updated Apr 14 2014 - 1 reports

ACTELION : Issues invitation to 2014 annual general meeting of shareholders

Release date- 11042014 - ALLSCHWIL/ BASEL, SWITZERLAND - Actelion Ltd (SIX: ATLN) today issued the formal invitation to the upcoming Annual General Meeting (AGM) of shareholders on behalf of the Board of Directors.The meeting will take place on Thursday, ... [Published 4 Traders - Apr 14 2014]

Quotes

SRF Board Chairman Luke Evnin " is the single most successful fundraising and awareness building event for scleroderma" says Evnin
...SRF's cooperative approach to research is making possible for talented scientists from leading institutions across the nation and around the world: "Our partnerships are helping to develop an understanding of how scleroderma begins, how it progresses and what can be done to slow, halt or reverse the disease process. "
...Further launches throughout Europe are forthcoming, as well as a regulatory filing for Opsumit in Japan." Mr Clozel concluded: "Based on this good start to the year, Actelion will be well positioned to review its guidance for core earnings growth by mid-year."
'The approval came very quickly,' says Thomson. "If a company has drugs that will make a difference, and drugs to treat high, unmet medical needs, you could get approval more quickly."

More Content

All (219) | News (202) | Reports (0) | Blogs (8) | Audio/Video (0) | Fact Sheets (2) | Press Releases (6)
sort by: Date | Relevance
Scientists and Headlining Entertainers Unite to... [Published Digital Journal - Apr 18 2014]
Scientists and Headlining Entertainers Unite to... [Published ADVFN India - Apr 18 2014]
Actelion expands its PAH franchise in first qua... [Published MedNous - Apr 18 2014]
Good News for Cleveland BioLabs [Published Yahoo! Finance - Apr 17 2014]
Actelion's CEO Discusses Q1 2014 Results - Earn... [Published Seeking Alpha - Apr 17 2014]
European Stocks Rally For Modest Weekly Gain [Published RTTNews.com - Apr 17 2014]
Swiss Stocks Turn Higher, Led By UBS [Published RTTNews.com - Apr 17 2014]
Using a Drug-Safety Tool to Prevent Competition [Published New England Journal of Medicine - Apr 17 2014]
Actelion Beats on Q1 Earnings and Sales [Published Yahoo! Finance - Apr 17 2014]
Actelion posts strong first-quarter 2014 results [Published Pharma Letter - Apr 17 2014]
What Falling Estimates & Price Mean for Discove... [Published Yahoo! Finance - Apr 17 2014]
Actelion flags possible mid-year guidance upgra... [Published Big News Network - Apr 17 2014]
Actelion Ltd gives FY 2014 and FY 2015 core ear... [Published Reuters UK - Apr 17 2014]
European Market Update: Participation Is Light ... [Published Action Forex - Apr 17 2014]
Actelion's first-quarter profit, sales rise, be... [Published FirstWord Pharma - Apr 17 2014]
S&P 500 Futures Fall on Google, IBM Sales Miss ... [Published Washington Post - Apr 17 2014]
EUROPEAN EQUITY OPENING HEADLINES INCLUDING: As... [Published Proactiveinvestors United Kingdom RSS feed - Apr 17 2014]
European Bourses Not Enjoying Bullish Winds Fro... [Published OANDA Forex Blog - Apr 17 2014]
BRIEF-Actelion rises 2 pct after Q1 results beat [Published Reuters UK - Apr 17 2014]
BRIEF-Actelion rises 2 pct after Q1 results beat [Published Reuters - Apr 17 2014]
Europe Stock-Index Futures Little Changed on Fe... [Published Bloomberg - Apr 17 2014]
Actelion Beats First-Quarter Earnings Expectations [Published DailyMe.Com - Apr 17 2014]
European Stocks Seen Pausing After Rally [Published RTTNews.com - Apr 17 2014]
UPDATE 1-Actelion flags possible mid-year guida... [Published Reuters - Apr 17 2014]
Actelion Q1 Profit, Revenue Rise - Quick Facts [Published RTTNews.com - Apr 17 2014]
Actelion flags possible mid-year guidance upgra... [Published Reuters UK - Apr 17 2014]
BB Biotech: Solid fundamental progress in the f... [Published Nasdaq - Apr 17 2014]
Actelion : announces first quarter 2014 financi... [Published 4 Traders - Apr 17 2014]
Swiss Stocks Crawl Higher Despite Credit Suisse [Published RTTNews.com - Apr 16 2014]
Zurich Stocks Slide Tuesday [Published 4 Traders - Apr 15 2014]
1 2 3 4 5 6 7 8
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
European Bourses Not Enjoying Bullish Winds Fro... [Published OANDA Forex Blog - Apr 17 2014]
European stocks were little changed, with the Stoxx Europe 600 Index heading for a weekly gain, as Federal Reserve Chair Janet Yellen reiterated the central bank will continue to support the economy. U.S. index futures were also little changed, while ...
Another REMS Antitrust Lawsuit: Mylan Sues Celg... [Published FDA Law Blog - Apr 04 2014]
By Kurt R. Karst –In a 17-count, 84-page Complaint filed earlier this week in the U.S. District Court for the District of New Jersey, Mylan Pharmaceuticals Inc. (“Mylan”) alleges that Celgene Corporation (“Celgene”) has violated federal and state antitrust ...
Orphan designation: Macitentan, for the: Treatm... [Published Orphan designations - Apr 01 2014]
On 27 September 2011, orphan designation (EU/3/11/909) was granted by the European Commission to Actelion Registration Limited, United Kingdom, for macitentan for the treatment of pulmonary arterial hypertension. ...
Novimmune Appoints Andrew J. Oakley as CFO [Published PR Newswire: Health - Mar 12 2014]
GENEVA, March 12, 2014 /PRNewswire/ --Novimmune S.A announced today that Andrew J. Oakley has joined the company as Chief Financial Officer.Andrew Oakley, an Australian national, who most recently served as the CFO of Swiss-based Actelion Ltd, is also ...
Osage Venture Partners promotes Drahms and hire... [Published PE Hub Blog - Mar 05 2014]
Osage Venture Partners has promoted David Drahms to principal and hired Michael Phelan as a venture partner. Drahms joined Osage Venture Partners in 2005 while Phelan was previously CEO of SevOne . PRESS RELEASE Bala Cynwyd, PA – Osage Venture Partners ...
1 2

Press Releases

sort by: Date | Relevance
The Zacks Analyst Blog Highlights: Sangamo BioS... [Published Financial Services - Jan 14 2014]
The Zacks Analyst Blog Highlights:Bayer, Seattl... [Published Financial Services - Nov 29 2013]
The Zacks Analyst Blog Highlights: Manitex Inte... [Published Financial Services - Nov 27 2013]
The Zacks Analyst Blog Highlights: Actelion, Ba... [Published Financial Services - Nov 06 2013]
The Zacks Analyst Blog Highlights:Dendreon, JPM... [Published Financial Services - Oct 30 2013]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.